Deal Snapshot
Alcon Closed USD 770m Acquisition of Aerie Pharmaceuticals
Wednesday 23 November 2022

Switzerland-based eye care company Alcon (SIX: ALC) (NYSE: ALC) has closed the acquisition of US-based ophthalmic-focussed pharmaceutical company Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) in a deal valued at USD 770m, the company said.

This transaction affirms Alcon's commitment to the ophthalmic pharmaceutical space and is expected to add broader pharmaceutical R and D capabilities to Alcon's existing commercial expertise, maximising the value of its diversified portfolio.

Date Published: 23/11/2022